Olanzapine in the Treatment of Anorexia Nervosa

Northwell Health

Status and phase: Completed; Phase 4

Conditions: Anorexia Nervosa

Treatments: Drug: olanzapine; Drug: placebo

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT00592930

Lilly F1D-US-X166

99-04-072

Details and patient eligibility

About

This study compared 10 weeks of treatment with olanzapine versus placebo in adolescent females with anorexia nervosa-restricting type who were undergoing acute treatment on an inpatient unit or a day hospital program that specializes in the treatment of eating disorders.

Sex: Female

Ages: 12 to 23 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Females, ages 12-23

Exclusion criteria

• Binge-purge type

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

20 participants in 2 patient groups, including a placebo group

1

Experimental group

Description:

olanzapine

Treatment:

Drug: olanzapine

2

Placebo Comparator group

Description:

matching placebo

Treatment:

Drug: placebo